An
Jeffrey Lewis only raised his concerns to AbbVie about potential regulatory violations, failing to satisfy the notice requirement needed to state a claim for unlawful retaliation under §31 U.S.C. §3730(h), Judge Joshua P. Kolar said. And the allegedly unlawful scheme implies that AbbVie risked violating US Food and Drug Administration regulations about off-label marketing, rather than submitting false claims to the government.
The unanimous US Court of Appeals ...